Trianni develops humanized mice used in drug trials, AbCellera said. Its mice help drug developers investigate multispecific antibodies and immune tolerance as well as target new epitopes.

Adding Trianni to its business expands AbCellera's platform, which currently includes microfluidic single-cell screening, repertoire sequencing, and bispecific protein engineering, according to the firm.

AbCellera raises $105M to fund antibody drug development
Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity...

AbCellera partners with Lilly for antibody discovery
AbCellera Biologics has joined forces with Eli Lilly on a multiyear initiative to identify antibodies for up to nine therapeutic targets.

AbCellera secures COVID-19 drug development funding
AbCellera Biologics has secured $175.6 million Canadian ($124.7 million U.S.) from the Canadian government's Innovation, Science, and Economic...